 |
Medical Devices
With continuing advances in biomaterials research and surgical techniques, the global medical device industry continues to observe fast and positive growth. As an emerging player in the Asian medical device landscape, Singapore plays host to world-class technology companies such as Edwards Lifesciences, Medtronic and Siemens Medical instruments. Innovative start-ups such as BioMers and Osteopore International have also found a fertile community to seed and grow their technology, thus contributing to the local R&D and manufacturing landscape.
NUS Research Capabilities
NUS maintains a close association with the Singapore National University Hospital (NUH), a world-class surgical hospital as well as a clinical training and research centre. Prominent participants come from the Duke-NUS Graduate School of Medicine, the NUS Yong Loo Lin School of Medicine, the NUS Faculty of Dentistry, Faculty of Engineering and Faculty of Science
Strategic partnerships between clinical practitioners and research expertise can give rise to remarkable medical device innovations. Recent breakthroughs have emerged from these collaborations in the areas of cardiology, orthopaedic surgery and biomaterial sciences.
|
Highlights
|
Current Research Projects
|
| |
|
|
Diagnostics
The field of medical diagnostics has recently seen immense growth due to advances in genomics, proteomics and bioinformatics. With this sector slated as a promising area of growth, Singapore’s biomedical hub has been attracting participation from established industry giants such as BioRad and Roche.
NUS Research Capabilities
NUS has amassed a diverse portfolio of diagnostic tools and research that ranges from molecular and tissue diagnostics, to biomedical imaging and computational biology. Key inventions and technologies that have seen recent breakthroughs in NUS labs include biosensors, medical imaging and bioinformatics. By collaborating with the university’s diverse faculty in the area of Life Science, researchers within the Departments of Electrical and Mechanical Engineering as well as the Faculty of Science have been actively developing new technologies to make drug discovery more efficient and contribute to the advancement of personalised medicine.
|
Highlights
|
Areas of Research
 |
Click to see our latest inventions in disease diagnostics |
 |
|
|
|
|
 |
|
|
 | |
|
|
|
|
|
|
Cancer Detection Directly from Blood, Using Microfluidics Technology Developed at NUS |
|
|
|
|
|
|
Prof Lim Chwee Teck has developed a high-throughput cell separation technique for sorting circulating tumor cells (CTCs) from blood using microfluidics. The separation relies on the interplay between the inertial lift forces (due to the large cell size) and the Dean drag force (due to the spiral geometry) to equilibrate cells in distinct positions within the microchannel cross-section. By designing an appropriate bifurcated outlet, the cells can then be collected separately based on their size.
|
This technique is applied to separate CTCs which are larger in size from blood cells for early cancer detection and monitoring treatment efficiency. No chemical modifications of the channel or antibody labeling is required. This further reduces processing time and cost, also making the device ideal for use in resource limited settings. This device also allows easy collection of the viable CTCs after separation in a single step which makes it ideal for subsequent biological assays. |
|
|
|
|
|
|
| |
|
|
Therapeutics
Modern medicine has gone through revolutionary changes in recent years. Treatment of diseases is no longer confined to pills and injections but has also incorporated biologics therapy. Committed to being the leading biomedical hub in Asia, Singapore plays host to reputable biomedical sciences companies such as Abbott, AstraZeneca and Genzyme. Remarkable progress in translational and clinical research has been made based on a strong scientific community focusing on key areas such as cancer, genomics, infectious diseases and immunology.
NUS Research Capabilities
Established relationships between NUS and its network of partners such as Duke-NUS, Abbott, AstraZeneca and Novartis Institute have created a collaborative framework focusing on therapeutics research such as cancer and infectious diseases. The Cancer Science Institute of Singapore at NUS takes a leading role in synergising existing research efforts, especially in the areas of experimental therapeutics and cancer biology. The confluence of expertise from the Faculty of Science and Medicine has also advanced the research of infectious diseases such as HIV/AIDS and malaria.
|
Highlights
|
Areas of Research
|
 |
|
|
 |
|
|
Horseshoe crab holds secret to protein that fights infection
Professor Ding Jeak and colleagues pioneer discoveries that elucidate host immune responses to bacterial infection. Along with colleague Professor Ho Bow, Prof Ding has successfully commercialized technology from their years of research at NUS. Read more about their research to market story in our Featured Technology.
Read more about Prof Ding's work here.
The Straits Times article, 31 July 2007, pH4
|
|
 |
|
|
 |
|
|
|
|
|
|
|
Phenotypic Drug Discovery (PD2) Collaboration with Eli Lilly
Researchers with drug compounds or biologically active candidates for disease indications can take part in this collaborative drug discovery effort by Eli Lilly. This is a no-cost evaluation of your compounds in Lilly's disease-relevant phenotypic screens. All IP rights will remain with the institution/submitter at all times, and all compound information will remain confidential and inaccessible to the Lilly staff who will handle the compounds.
Through a collaborative agreement with NUS and ILO, Eli Lilly is now able to offer NUS researchers access to this candidate drug screening program.
To submit your proprietary compounds for screening and evaluation, please create an account here.
NUS Researchers can use affiliation code 8a85ajoj
For more information, download the executive summary of the PD2 program here.
Visit Eli Lilly's PD2 web site here.
|
|
|
|
|
|
| |
 |
Research Tools
Whether it is a single reagent or a widely applicable assay system, biomedical research is in the business of building tools. Many innovative reagents and assays developed in discovery research labs end up shelved or as proprietary industry know how. R2M promotes the sharing and dissemination of laboratory tested technologies and reagents to benefit and promote research across the world. Through this platform, R2M intends to establish a waystation to make research tools visible and available whilst providing intellectual property protection and compensation for researchers.
NUS Antibody Repository
Biomedical research is forwarding the frontiers of molecular medicine and personalized genomics every day. As we come to a greater understanding of the way genes interact and control our biology, we open new doors for research and therapy using molecular tools. High quality antibodies with unique specificities and functions are being constantly generated in research labs across the world. The goal of the NUS Antibody repository is to facilitate the collection and distribution of these valuable reagents to the research and commercial community.
For the researcher, we will aid in the protection of your intellectual property interests whilst providing a platform for making your reagent visible, accessible and for sale to the community.
For customers and commercial entities, we are marketing these reagents to both the research and industrial community. For information about licensing an antibody from our repository, please contact us.
|
Antibodies
|
|
|
|
|
|
Have you developed a great Antibody? We can help you distribute and/or commercialize it.
Look at our criteria and follow our guidelines for online submission.
|
|
|
|
|
| |
Research Tools in Development
| |
Printable
